"Commercially available probiotics such as VSL#3 or Flora-Q which are mixtures of several different bacterial species have been used for treating small intestinal bacterial overgrowth and IBS, but their effectiveness is not known.
Bifidobacterium infantis 35624 is the only probiotic that has been demonstrated to be effective for treating patients with IBS." -
www.medicinenet.com/irritable_bowel_syndrome/page6.htm March 23, 2009 – A review by researchers at Northwestern University (Chicago, IL.) and University of Michigan (Ann Arbor, MI) of the utility of probiotics in the treatment of Irritable Bowel Syndrome (IBS) found that Bifidobacterium infantis 35624 was the only probiotic strain out of 13 different individual strains or preparations reviewed to significantly improve symptoms of IBS, including abdominal pain, bloating and bowel movement difficulty. Bifidobacterium infantis 35624 is marketed as Bifantis® and can be found in a daily probiotic supplement by Procter & Gamble. The researchers reviewed 16 random-controlled-studies, evaluating the efficacy, safety and tolerability of probiotics in the treatment of IBS. With the exception of the Bifidobacterium infantis 35624 studies, researchers found the other trials did not use an appropriate study design and did not adequately report adverse events.
"Probiotics are gaining popularity for the treatment of multiple gastrointestinal disorders, including IBS," said Darren. M Brenner, MD, Division of Gastroenterology and Department of Internal Medicine, at Northwestern University and lead investigator of this study. "After assessment of the methodological and statistical designs of these studies, B. infantis 35624 was the only probiotic that showed repeated efficacy."
Clinical evidence and support for Bifantis continues to grow
Bifidobacterium infantis 35624, discovered in the early 1990s by microbiologists at Alimentary Health in Cork, Ireland in partnership with P&G, has been independently tested and evaluated in several clinical trials conducted with humans. This latest review provides continued clinical evidence of Bifantis efficacy in helping to manage a range of gastrointestinal issues including abdominal pain, bloating, constipation, diarrhea, gas and urgency. Bifantis efficacy data has been published or referenced in several medical journals, including the American Journal of Gastroenterology-2 , Gastroenterology-3 , New England Journal of Medicine-4 , Public Library of Science ( PLoS)-5 and Nutrition in Clinical Practice-6. Bifantis is found in the number one gastroenterologist recommended probiotic supplement in the United States-7 .
1. Am J Gastroenterology advance online publication, 10 March 2009; doi: 10.1038/ajg.2009.25
2. Whorwell PJ, Altringer I, Morel J, et al, Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Women with Irritable Bowel Syndrome; Am. J Gastroenterology, 2006:101(7): 1581-1590
3. O'Mahony L, McCarthy J, Kelly P, et al, Lactobacillus and Bifidobacterium in Irritable Bowel Syndrome: Symptom Responses and Relationships to Cytokine Profiles, Gastroenterology, 2005;128 (3): 541-551
4. E. A. Mayer, M.D., Irritable Bowel Syndrome; N Engl J Med 2008;358;1692-9
5. O'Mahony C, Scully P, O'Mahony D, Murphy S, O'Brien F, et al. (2008) Commensal-Induced Regulatory T Cells Mediate Protection against Pathogen-Stimulated NF-kB Activation. PLoS Pathog 4(8): e1000112. doi:10.1371/journal.ppat.1000112
6. Arnold Wald and David Rakel; Behavioral and Complementary Approaches for the Treatment of Irritable Bowel Syndrome; Nutrition In Clinical Practice; 2008:23 (3): 284 - 292
7. Among those who recommended a brand of probiotic in 2008, Wolters Kulwer survey, 2008
8. LadabaumU. Irritable Bowel Syndrome. Adv Stud Med 2004; 4(3):128-134; Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA Technical Review of Irritable Bowel Syndrome. Gastroenterolgy 2002;123:2108-2131; Johns Hopkins Resource Center, Digestive Diseases Library. Monograph on Irritable Bowel Syndrome (2004). www.hopkins-gi.org
foodconsumer.org/7777/8888/F_ood_C_hemicals_37/Review_of_probiotic_trial_research_finds_only_Bifantis_able_to_claim_efficacy_for_IBS_symptoms.shtml